샘플 요청 목록

 카트 문의
시장보고서
상품코드
1786580

세계의 여성 불임 진단 시장

Female Infertility Diagnosis
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 176 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

여성 불임 진단 세계 시장은 2030년까지 69억 달러에 달할 전망

2024년에 47억 달러로 추정되는 여성 불임 진단 세계 시장은 2024-2030년 분석 기간 동안 CAGR 6.7%로 성장하여 2030년에는 69억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 난소 예비력 검사는 CAGR 5.4%를 기록하며 분석 기간 종료시에는 26억 달러에 달할 것으로 예측됩니다. 자궁난관조영 검사 부문의 성장률은 분석 기간 동안 CAGR 8.8%로 추정됩니다.

미국 시장은 13억 달러로 추정, 중국은 CAGR 10.3%로 성장 예측

미국의 여성 불임 진단 시장은 2024년에 13억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 14억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간 2024-2030년 CAGR은 10.3%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 3.4%와 6.4%로 예측됩니다. 유럽에서는 독일이 CAGR 4.4%로 성장할 것으로 예측됩니다.

세계의 여성 불임 진단 시장 - 주요 동향과 촉진요인 정리

여성 불임 진단이 현대 의료에서 그 어느 때보다 주목받는 이유는 무엇일까?

세계적으로 불임이 증가함에 따라 여성 불임 진단은 생식 의료 혁신의 최전선에 위치하고 있습니다. 전 세계적으로 가임기 부부의 약 8-12%가 불임에 시달리고 있으며, 배란장애, 자궁내막증, 자궁이상, 난소예비력 저하 등의 근본적인 원인을 밝히기 위해 여성들은 점점 더 많은 진단적 평가를 받고 있습니다. 출산 지연, 도시화, 의식 향상 등 사회 규범의 변화가 진단율을 높이는 요인으로 작용하고 있습니다. 여성들이 고령에 임신을 시도하는 경우가 많아지면서 노화에 따른 불임과 호르몬 불균형이 눈에 띄게 증가함에 따라 종합적인 진단 전략이 필요하게 되었습니다. 현재 임상 워크플로는 호르몬 수치 검사, 경질 초음파 검사 등 기본적인 평가부터 시작하여 자궁난관조영술(HSG), 복강경 검사, 유전자 검사, 난소예비력 평가 등 첨단 기술로 나아가는 것이 일반적입니다. 특히 도심을 중심으로 한 곳에서 빠른 진단 서비스를 제공하는 불임치료 전문 클리닉 증가가 이러한 수요를 부추기고 있습니다. 신흥국에서는 의료 문해력 향상과 정부 지원 생식 건강 프로그램이 사회적 낙인을 없애고 더 많은 여성들이 적시에 진단 지원을 받도록 유도하여 시장 확대에 더욱 박차를 가하고 있습니다.

진단 기술은 여성 불임 검사의 미래를 어떻게 형성하고 있는가?

더 빠르고, 더 정확하고, 더 최소침습적 평가를 가능하게 하는 기술의 발전으로 여성 불임 진단의 상황은 빠르게 변화하고 있습니다. 인공지능(AI)과 머신러닝은 초음파 영상 진단과 호르몬 분석에 적용되어 진단 정확도와 패턴 인식을 높이고 있습니다. 3D 및 4D 초음파 영상 진단과 같은 기술 혁신은 자궁과 난소의 구조에 대한 탁월한 해부학적 인사이트를 제공하며, 첨단 복강경 검사 도구는 골반의 이상을 실시간으로 고화질로 시각화합니다. 또한, 보다 높은 민감도와 특이도를 가진 호르몬 측정 키트의 개발로 에스트로겐, FSH, LH, AMH, 프로락틴 수치의 이상 징후를 쉽게 감지할 수 있게 되었습니다. 유전학적 검사도 특히 반복 유산과 조기 난소 부전과 관련된 염색체 및 유전 질환을 확인하는 데 있어 점점 더 많은 관련성이 높아지고 있습니다. AMH 수치와 배란 추적을 위한 가정용 불임 검사 키트의 보급은 특히 기술에 정통하고 프라이버시를 중시하는 소비자들 사이에서 이용 편의성을 높이고 있습니다. 이러한 기술 혁신과 함께 통합 디지털 플랫폼과 원격의료 상담은 검사 결과를 통합하고, 전문의와의 원격 상담을 용이하게 하며, 여성의 생식 프로파일을 기반으로 개인화된 진단 경로를 가능하게함으로써 진단 여정을 간소화합니다.

어떤 사회적, 문화적 역학이 전 세계 진단 수요를 형성하고 있는가?

불임과 모성에 대한 사회적 태도는 여성이 언제, 어디서, 어떻게 불임 진단을 받을지 결정하는 데 중요한 역할을 합니다. 많은 선진국에서 보조생식술(ART)이 보편화되면서 여성들은 미래 가족계획을 위한 적극적인 조치로 조기에 진단 검사를 받기를 원하고 있습니다. 결혼이 늦어지고, 교육, 경력개발, 경제적 안정 등 우선순위가 바뀌면서 20대 후반에서 30대에 불임 검사를 받는 여성들이 많아지고, 증상이 나타나기 전에 불임 검사를 받는 경우가 많습니다. 이와는 대조적으로, 전통사회에서 불임은 여전히 높은 낙인이 찍혀 있고, 여성은 임신을 해야 한다는 사회적 압력에 직면할 수 있습니다. 이러한 문화적 압력에 대응하기 위해 교육 캠페인, 불임 인식 개선 주간, NGO 주도의 아웃리치 프로그램 등 불임의 도덕적 성격이 아닌 의학적 성격을 강조하는 캠페인이 늘어나고 있습니다. 또한 지역, 소득, 의료 인프라에 따른 접근성 격차는 시장 침투에 지속적으로 영향을 미치고 있습니다. 중저소득 국가에서는 도시와 농촌의 격차가 양질의 진단약에 대한 접근성을 좌우하는 경우가 많지만, 이동 진료소 및 보조금 지원 검사 이니셔티브가 이러한 격차를 해소하기 시작했습니다. 불임 옹호 활동, 유명인의 공개 발언, 미디어 캠페인 등도 이 주제를 주류로 끌어올려 금기를 깨고 다양한 계층의 진단 수요에 박차를 가하고 있습니다.

지역과 인구통계에 관계없이 시장 성장을 가속하는 핵심 요인은 무엇인가?

여성 불임 진단 시장의 성장은 의료 기술의 발전, 환자층의 변화, 의료 시스템의 우선순위와 관련된 몇 가지 요인에 의해 주도되고 있습니다. 가장 중요한 촉진요인 중 하나는 첫 출산 시 산모의 연령이 증가하고 있으며, 이는 본질적으로 불임 합병증의 가능성을 높이고 더 일찍 그리고 더 자주 진단 평가를 촉구하고 있습니다. 또한, 불임치료에 특화된 의료보험과 보험 환급이 널리 보급되면서 더 많은 사람들이 고비용의 진단을 쉽게 이용할 수 있게 되었습니다. 난소 예비력을 평가하기 위한 AMH 검사, 생식 장애 유전자 패널의 사용 등 진단의 정확도가 향상됨에 따라 조기 가임력 계획에 있어 진단이 필수적입니다. 진단과 치료를 일괄적으로 제공하는 불임치료센터가 급증하면서 특히 도시지역과 경력단절 여성들의 편의성과 임신율을 높이고 있습니다. 또 다른 중요한 요인은 전 세계적으로 ART 주기가 급증하고 있는 상황에서 최적의 치료 프로토콜을 선택하기 위해서는 정확한 진단이 필수적입니다. 정부와 민간 기업들도 불임 치료 인프라 확충에 투자하고 있으며, 인도, 중국, 중동 일부 지역 등에서는 조기 검진 및 인식 개선을 위한 노력을 기울이고 있습니다. 마지막으로, 밀레니얼 세대와 Z세대의 호르몬 및 생식 건강에 대한 인식이 높아지면서 시장 기반이 확대되고 개인화된 데이터 기반 진단 솔루션에 대한 수요를 창출하고 있습니다.

부문

검사(난소 예비력 검사, 자궁난관조영 검사, 호르몬 검사, 기타 검사)

조사 대상 기업 사례

  • Bayer AG
  • Carrot Fertility
  • CCRM Fertility
  • Dallas Fort Worth Fertility Associates
  • Extend Fertility
  • Ferring Pharmaceuticals
  • Hertility Health
  • Institute for Human Reproduction
  • Las Vegas Fertility
  • Main Line Fertility
  • Mankind Pharma
  • Merck KGaA
  • Novartis International AG
  • Overlake Reproductive Health
  • Pacific Fertility Center Los Angeles(PFCLA)
  • Pfizer Inc.
  • Proov
  • San Diego Fertility Center
  • Selectivity
  • Wisconsin Fertility Institute

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 산업 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)에 따른 기업의 경쟁 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.21

Global Female Infertility Diagnosis Market to Reach US$6.9 Billion by 2030

The global market for Female Infertility Diagnosis estimated at US$4.7 Billion in the year 2024, is expected to reach US$6.9 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Ovarian Reserve Testing, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Hysterosalpingography Test segment is estimated at 8.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 10.3% CAGR

The Female Infertility Diagnosis market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 10.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Female Infertility Diagnosis Market - Key Trends & Drivers Summarized

Why Is Female Infertility Diagnosis Gaining Unprecedented Attention in Modern Healthcare?

The rising global prevalence of infertility is placing female infertility diagnosis at the forefront of reproductive healthcare innovation. With an estimated 8-12% of reproductive-aged couples affected by infertility worldwide, women increasingly undergo diagnostic evaluations to uncover underlying causes such as ovulatory disorders, endometriosis, uterine abnormalities, or diminished ovarian reserve. Changing societal norms-including delayed childbearing, urbanization, and increased awareness-have further contributed to higher diagnosis rates. As women now often attempt pregnancy at older ages, age-related infertility and hormonal imbalances have become more prominent, necessitating comprehensive diagnostic strategies. Clinical workflows now typically begin with basic evaluations such as hormone level testing and transvaginal ultrasounds, progressing to advanced techniques like hysterosalpingography (HSG), laparoscopy, genetic screening, and ovarian reserve assessments. This demand is bolstered by a growing number of specialized fertility clinics, particularly in urban centers, offering rapid diagnostic services under one roof. In developing countries, rising healthcare literacy and government-backed reproductive health programs are helping dismantle social stigmas and encouraging more women to seek timely diagnostic support, adding further momentum to the market’s expansion.

How Is Diagnostic Technology Shaping the Future of Female Fertility Assessments?

The landscape of female infertility diagnosis is being rapidly transformed by technological advancements that enable earlier, more accurate, and minimally invasive evaluations. Artificial intelligence (AI) and machine learning are being applied to ultrasound imaging and hormone analytics, enhancing diagnostic precision and pattern recognition. Innovations like 3D and 4D ultrasound imaging are providing superior anatomical insights into uterine and ovarian structures, while advanced laparoscopy tools are offering real-time, high-definition visualization of pelvic anomalies. Moreover, the development of hormone assay kits with higher sensitivity and specificity has made it easier to detect irregularities in estrogen, FSH, LH, AMH, and prolactin levels. Genetic testing is also becoming increasingly relevant, particularly in identifying chromosomal or hereditary conditions linked to recurrent miscarriages or premature ovarian failure. The proliferation of at-home fertility test kits for AMH levels or ovulation tracking is enhancing accessibility, particularly among tech-savvy and privacy-conscious consumers. Alongside these innovations, integrated digital platforms and telehealth consultations are streamlining the diagnostic journey by consolidating test results, facilitating remote consultations with specialists, and enabling personalized diagnostic pathways based on a woman’s reproductive profile.

What Social and Cultural Dynamics Are Shaping Diagnostic Demand Worldwide?

Social attitudes toward fertility and motherhood are playing a critical role in determining how, when, and where women seek infertility diagnoses. In many developed nations, the normalization of assisted reproductive technologies (ART) has prompted women to pursue earlier diagnostic testing as a proactive step toward future family planning. Delayed marriages and shifting priorities-such as education, career development, and financial stability-are influencing women to seek fertility assessments in their late twenties and thirties, often before symptoms arise. In contrast, in traditional societies, infertility remains highly stigmatized, and women may face immense societal pressure to conceive, pushing them to seek diagnosis quickly-often in secrecy or without adequate information. This cultural pressure is increasingly being countered by educational campaigns, fertility awareness weeks, and NGO-led outreach programs that emphasize the medical, not moral, nature of infertility. Additionally, access disparities-based on geography, income, and healthcare infrastructure-continue to influence market penetration. In low- and middle-income countries, urban-rural divides often determine access to quality diagnostics, though mobile clinics and subsidized testing initiatives are beginning to bridge these gaps. Fertility advocacy, celebrity openness, and media campaigns are also making the topic more mainstream, breaking taboos and fueling diagnostic demand across diverse demographics.

Which Core Factors Are Propelling Market Growth Across Regions and Demographics?

The growth in the Female Infertility Diagnosis market is driven by several factors tied to medical technology evolution, shifting patient demographics, and healthcare system priorities. One of the most significant drivers is the increasing maternal age at first childbirth, which inherently raises the likelihood of fertility complications and prompts earlier and more frequent diagnostic evaluations. The widespread availability of fertility-focused health insurance and reimbursement policies in developed markets is also making high-cost diagnostics more accessible to a larger population. Advances in diagnostic accuracy, including the use of AMH testing to assess ovarian reserve and genetic panels for reproductive disorders, are making diagnostics indispensable in early fertility planning. The proliferation of fertility centers offering bundled diagnostic and treatment services under one umbrella is enhancing convenience and uptake, particularly among urban and career-oriented women. Another critical factor is the surge in ART cycles globally, where precise diagnosis is essential for selecting optimal treatment protocols. Governments and private players are also investing in expanding fertility infrastructure, with initiatives in countries like India, China, and parts of the Middle East targeting early screening and awareness. Finally, growing awareness of hormonal and reproductive health among millennials and Gen Z, who are more likely to engage in proactive health behaviors, is expanding the market base and creating demand for personalized, data-driven diagnostic solutions.

SCOPE OF STUDY:

The report analyzes the Female Infertility Diagnosis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test (Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing, Other Tests)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • Bayer AG
  • Carrot Fertility
  • CCRM Fertility
  • Dallas Fort Worth Fertility Associates
  • Extend Fertility
  • Ferring Pharmaceuticals
  • Hertility Health
  • Institute for Human Reproduction
  • Las Vegas Fertility
  • Main Line Fertility
  • Mankind Pharma
  • Merck KGaA
  • Novartis International AG
  • Overlake Reproductive Health
  • Pacific Fertility Center Los Angeles (PFCLA)
  • Pfizer Inc.
  • Proov
  • San Diego Fertility Center
  • Selectivity
  • Wisconsin Fertility Institute

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Female Infertility Diagnosis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Maternal Age Trends Throw the Spotlight on Early and Accurate Female Infertility Diagnosis
    • Delayed Family Planning Among Urban Women Spurs Demand for Comprehensive Fertility Assessments
    • Increased Awareness and Social Acceptance of Infertility Issues Strengthens the Business Case for Diagnostic Services
    • Advancements in Hormonal Biomarkers and Genetic Testing Expand Addressable Market for Precision Diagnostics
    • Growing Integration of AI and Machine Learning in Reproductive Health Drives Adoption of Predictive Diagnostic Tools
    • Access to Fertility Services in Emerging Economies Generates New Opportunities for Diagnostic Market Penetration
    • Surge in In Vitro Fertilization (IVF) Cycles Accelerates Demand for Pre-IVF Diagnostic Workups
    • Healthcare Policy Reforms and Insurance Coverage in Developed Markets Propel Growth of Diagnostic Procedures
    • Rise in Polycystic Ovary Syndrome (PCOS) and Endometriosis Incidence Fuels Demand for Early Diagnostic Interventions
    • Telehealth and At-Home Diagnostic Kits Drive Adoption of Convenient and Non-Invasive Fertility Testing Solutions
    • Clinical Focus on Personalized Reproductive Medicine Sustains Growth in Advanced Diagnostic Methodologies
    • Diagnostic Innovations in Ovarian Reserve and Tubal Patency Testing Broaden Scope for Early Detection
    • Psychological and Emotional Burdens of Infertility Create Opportunities for Integrated Diagnosis and Counseling Services
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Female Infertility Diagnosis Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Female Infertility Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Female Infertility Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Ovarian Reserve Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Ovarian Reserve Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Ovarian Reserve Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hysterosalpingography Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hysterosalpingography Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Hysterosalpingography Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hormone Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hormone Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hormone Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: USA 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: Canada 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • JAPAN
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: Japan 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • CHINA
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: China 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • EUROPE
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Female Infertility Diagnosis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Europe 15-Year Perspective for Female Infertility Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Europe 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • FRANCE
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: France 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • GERMANY
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Germany 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Italy 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: UK 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 47: Spain Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Spain Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Spain 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 50: Russia Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Russia Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Russia 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Rest of Europe 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Female Infertility Diagnosis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Asia-Pacific 15-Year Perspective for Female Infertility Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Asia-Pacific 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 62: Australia Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Australia Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Australia 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • INDIA
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 65: India Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: India Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: India 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 68: South Korea Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: South Korea Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: South Korea 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Rest of Asia-Pacific Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Rest of Asia-Pacific 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Female Infertility Diagnosis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Latin America 15-Year Perspective for Female Infertility Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Latin America 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 80: Argentina Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Argentina Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Argentina 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 83: Brazil Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Brazil Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Brazil 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 86: Mexico Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Mexico Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Mexico 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Latin America Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Latin America 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Female Infertility Diagnosis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Middle East 15-Year Perspective for Female Infertility Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Middle East 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 98: Iran Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Iran Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Iran 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 101: Israel Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Israel Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Israel 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Saudi Arabia Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Saudi Arabia 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 107: UAE Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UAE Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UAE 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Middle East Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Middle East 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • AFRICA
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 113: Africa Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Africa Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Africa 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제